Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) announced that it has been granted a patent in India (Patent no. 319759) for its WaferiX™ drug delivery technology.

EddyLee1019Eddy Lee, executive chairman of iX Biopharma at the FY19 AGM. NextInsight photo.The patent will expire on 26 October 2030.

WaferiX™ is a multiple drug carrier platform technology that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e. placed under the tongue).

The compounds are delivered safely, conveniently and rapidly into the blood stream.


Produced via the Group’s proprietary freeze-drying technique, the porous and amorphous WaferiX™ matrix holding the active molecules is designed to collapse quickly within the sublingual space.

The molecules are then transported rapidly across the sublingual membrane into the blood vessels for a rapid onset of action.

In addition, the technology has also been proven to increase the bioavailability of drug actives as well as predictability of effect.

Stock price 

21 c

52-week range

16 – 29 c

Market cap

S$135 m

PE (ttm)

-

Dividend yield 

-

Year-to-date 
return

23%

Shares outstanding

644.6 m

Source: Bloomberg

With India’s grant of patent, iX Biopharma’s intellectual property rights for its sublingual wafer technology are now secured in key Asian markets including China, Singapore, South Korea, Malaysia, Indonesia and Japan.

Apart from Asia, iX Biopharma has amassed a portfolio of patents in other countries, namely Australia, New Zealand, Canada, South Africa, United Kingdom and countries in the European Union such as Germany, France, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland, as well as Finland.

EvanTan7.19Ms Eva Tan (photo), Director, Corporate and Commercial Strategy of iX Biopharma commented:

“Moving forward, the Group will continue to leverage on the vast commercial potential of WaferiX™ to develop novel treatment options in order to satisfy unmet medical needs.

"Supported by a broad and diversified patent portfolio of major markets countries, we are well-positioned to seek out potential export opportunities for WaferiX™ products by way of off-take agreements and out-licensing, so as to diversify our revenue streams and chart new avenues of growth.”

See also: 


Share Prices

Counter NameLastChange
AEM Holdings3.070-0.070
AusGroup0.0290.001
Avi-Tech Electronics0.395-0.005
Best World Int.1.360-
CEI0.870-0.020
China Sunsine0.380-
CNMC GoldMine0.210-0.010
CSE Global0.4850.010
Food Empire0.535-
Golden Energy0.170-
GSS Energy0.0790.002
ISDN Holdings0.230-0.005
ISOTeam0.130-0.002
IX Biopharma0.270-0.010
JB Foods0.490-
KSH Holdings0.330-
Medtecs Intl0.250-0.015
Moya Asia0.066-0.001
Nordic Group0.2400.005
Oxley Holdings0.245-
Procurri0.2800.010
REX International0.193-0.002
Riverstone2.010-0.230
Roxy-Pacific0.365-0.005
Sing Holdings0.3350.005
SingMedical0.2500.005
Straco Corp.0.5100.005
Sunningdale Tech0.9900.010
Sunpower Group0.475-0.005
The Trendlines0.111-
Tiong Seng0.1750.013
Uni-Asia Group0.560-0.060
Yangzijiang Shipbldg1.0100.015

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 352 guests and no members online